Roche Issues New Dosing Restrictions for Elevidys Over Fatal Liver Failure Risk

Strategic Insights -

Roche Holding AG has imposed new dosing restrictions on its gene therapy treatment, ELEVIDYStm, for non-ambulatory Duchenne muscular dystrophy (DMD) patients, following the identification of two fatal cases of acute liver failure (ALF). The company has halted treatment for non-ambulatory patients in both clinical and commercial settings, citing an unfavourable benefit-risk profile. The decision comes after a reassessment of the risks associated with ELEVIDYStm and other AAV-mediated gene therapies, which have been linked to liver failure in some patients. Despite the new restrictions, ambulatory DMD patients remain eligible for treatment, and Roche continues to work with health authorities, investigators, and physicians to mitigate any risks related to the use of ELEVIDYStm.

Key Takeaways:

  • Roche has imposed new dosing restrictions on ELEVIDYStm for non-ambulatory DMD patients in both clinical and commercial settings, following two fatal cases of ALF.
  • The restrictions do not impact treatment for ambulatory DMD patients of any age, who still have access to ELEVIDYStm.
  • The benefit-risk profile is unfavourable for non-ambulatory patients, according to Roche, citing an increased risk of liver failure.
  • The two fatal ALF cases occurred in non-ambulatory patients, out of approximately 140 non-ambulatory patients treated with ELEVIDYStm globally to date.
  • European regulators had requested a temporary clinical hold on ELEVIDYStm studies following the first case of fatal ALF, which is still in effect.
  • The dosing restrictions will also apply to future dosing of commercial non-ambulatory patients and will be implemented immediately for the ENVISION trial.

Statistics:

  • Approximately 180,000 people worldwide have DMD, with a male prevalence of approximately 1 in 5,000 boys born.
  • DMD is a rare, genetic, muscle-wasting disease that progresses rapidly from early childhood.
  • The two fatal ALF cases occurred in non-ambulatory patients.
  • ELEVIDYStm has been approved by regulatory authorities in eight Roche territories for the treatment of DMD.
  • Roche has entered into a global collaboration agreement with Sarepta Therapeutics, Inc. to commercialise ELEVIDYStm in territories outside the U.S.

Sources:

  • Roche (SIX: RO, ROG; OTCQX: RHHBY) press release (exact content and date not provided)
  • European regulators' request for temporary clinical hold on ELEVIDYStm studies (exact content and date not provided)
  • Roche and Sarepta Therapeutics, Inc. global collaboration agreement (exact content and date not provided)
  • Sarepta Therapeutics, Inc. press releases (exact content and date not provided)